EUVIMEDEUVIMED entdecken
Multizentrische Studie

Outcomes of hematopoietic stem cell transplantation in 813 pediatric patients with Fanconi anemia

Su Han Lum iD, Dirk-Jan Eikema, Brian Piepenbroek iD, Robert F Wynn, Sujith Samarasinghe, Arnaud Dalissier, Krysztof Kalwak iD, Mouhab Ayas iD, Rose-Marie Hamladji, Akif Yesilipek, Jean-Hugues Dalle, Duygu Uckan-Cetinkaya und 13 weitere

Blood · 19.09.2024 · 144 (12) · 1329-1342

DOI: 10.1182/blood.2023022751 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Blood, erschienen am 19.09.2024. Verfasst von Su Han Lum und 24 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom. Hauptthemen laut MEDLINE: Fanconi Anemia, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only established curative option for Fanconi anemia (FA)–associated bone marrow failure (BMF)/aplastic anemia (AA) and acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS). We performed a retrospective multicenter study on 813 children with FA undergoing first HSCT between 2010 and 2018. Median duration of follow-up was 3.7 years. Median age at transplant was 8.8 years (IQR, 6.5-18.1). Five-year overall survival (OS), event-free survival (EFS), and graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) were 83% (95% confidence interval [CI], 80-86), 78% (95% CI, 75-81), and 70% (95% CI, 67-74), respectively. OS was comparable between matched family donor (MFD; n = 441, 88%) and matched unrelated donor (MUD; n = 162, 86%) and was superior to that of mismatched family donor (MMFD) or mismatched unrelated donor (MMUD; n = 144, 72%) and haploidentical donor (HID; n = 66, 70%; P < .001). In multivariable analysis, a transplant indication of AML/MDS (vs AA/BMF), use of MMFD/MMUD and HID (vs MFD), and fludarabine-cyclophosphamide (FluCy) plus other conditioning (vs FluCy) independently predicted inferior OS, whereas alemtuzumab vs antithymocyte globulin was associated with better OS. Age ≥10 years was associated with worse EFS and GRFS. Cumulative incidences (CINs) of primary and secondary graft failure were 2% and 3% respectively. CINs of grade 3 to 4 acute GVHD and chronic GVHD were 12% and 8% respectively. The 5-year CIN of secondary malignancy was 2%. These data suggest that HSCT should be offered to patients with FA with AA/BMF at a younger age in the presence of a well-matched donor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fanconi AnemiaHematopoietic Stem Cell TransplantationGraft vs Host DiseaseHumansChildFemaleMaleAdolescentRetrospective StudiesChild, PreschoolTransplantation ConditioningTreatment OutcomeInfantLeukemia, Myeloid, AcuteUnrelated DonorsSurvival RateFollow-Up StudiesDisease-Free Survival

Autor:innen und Institutionen

  • Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Great North Children's Hospital, Newcastle upon Tyne, United Kingdom.
  • EBMT Statistical Unit, Leiden, The Netherlands.
  • EBMT Leiden Study Unit, Leiden, The Netherlands.
  • Royal Manchester Children's Hospital, Manchester, United Kingdom.
  • Great Ormond Street Hospital, London, United Kingdom.

ORCID-Profile: Su Han Lum, Brian Piepenbroek, Krysztof Kalwak, Mouhab Ayas, Khalid Halahleh, Elena Skorobogatova, Gülyüz Öztürk, Maura Faraci, Antonio Risitano

Zitieren

APA

Lum, S. H., Eikema, D. J., Piepenbroek, B., Wynn, R. F., Samarasinghe, S., Dalissier, A., Kalwak, K., Ayas, M., Hamladji, R. M., Yesilipek, A., Dalle, J. H., Uckan-Cetinkaya, D., Bierings, M., Kupesiz, A., Halahleh, K., Skorobogatova, E., Öztürk, G., Faraci, M., Renard, C., …, & Peffault de Latour, R. (2024). Outcomes of hematopoietic stem cell transplantation in 813 pediatric patients with Fanconi anemia. Blood, 144(12), 1329-1342. https://doi.org/10.1182/blood.2023022751

Vancouver

Lum SH, Eikema DJ, Piepenbroek B, Wynn RF, Samarasinghe S, Dalissier A, et al. Outcomes of hematopoietic stem cell transplantation in 813 pediatric patients with Fanconi anemia. Blood. 2024;144(12):1329-1342. doi:10.1182/blood.2023022751

BibTeX
@article{Lum2024,
  author = {Lum, Su Han and Eikema, Dirk-Jan and Piepenbroek, Brian and Wynn, Robert F and Samarasinghe, Sujith and Dalissier, Arnaud and Kalwak, Krysztof and Ayas, Mouhab and Hamladji, Rose-Marie and Yesilipek, Akif and Dalle, Jean-Hugues and Uckan-Cetinkaya, Duygu and Bierings, Marc and Kupesiz, Alphan and Halahleh, Khalid and Skorobogatova, Elena and Öztürk, Gülyüz and Faraci, Maura and Renard, Cecile and Evans, Pamela and Corbacioglu, Selim and Locatelli, Franco and Dufour, Carlo and Risitano, Antonio and Peffault de Latour, Régis},
  title = {Outcomes of hematopoietic stem cell transplantation in 813 pediatric patients with Fanconi anemia},
  journal = {Blood},
  year = {2024},
  volume = {144},
  number = {12},
  pages = {1329--1342},
  doi = {10.1182/blood.2023022751}
}
Kostenlos starten →